Trial reportAlzheimer's research & therapy2017
Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.
Trial report in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 149 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment in African Americans and Caucasians
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Who cites it
149 citing papers in PubMed, 4 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- Recent Advances in Graphene Oxide-Based on Organoid Culture as Disease Model and Cell Behavior - A Systematic Literature Review.International journal of nanomedicine · 2024Pooled it
- The Caribbean-Hispanic Alzheimer's disease brain transcriptome reveals ancestry-specific disease mechanisms.Neurobiology of disease · 2023Pooled it
- Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review.The European journal of neuroscience · 2022Pooled it
- Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer's Disease: A Correlative Meta-Analysis.Frontiers in aging neuroscience · 2019Pooled it
- CSF Cytokines in Aging, Multiple Sclerosis, and Dementia.Frontiers in immunology · 2019Trial
- Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease.Annals of neurology · 2026Observational
- APOE and plasma AD biomarkers: The role of genetic ancestry in Hispanics/Latinos.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Impaired LC-NE System-A Novel Molecular Mechanism Underlying Health Disparity and Increased Prevalence of Alzheimer's Disease Among African Americans.Diagnostics (Basel, Switzerland) · 2026Article
- Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort.JAMA network open · 2026Article
- Evaluation of a panel of plasma biomarkers for Alzheimer's disease in a diverse research cohort.Journal of Alzheimer's disease : JAD · 2026Article
- Successful strategies for supporting diverse representation in Alzheimer's disease research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- CSF estrogens' relationships to neuroinflammatory markers and brain networks in middle-aged and older black and white women.Journal of neuroinflammation · 2025Article
- Association Between Structural and Social Determinants of Health and Cognitive Functioning Among African Americans: the ARCHES Cohort.Journal of racial and ethnic health disparities · 2025Article
- Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.medRxiv : the preprint server for health sciences · 2025Article
- Associations of Longitudinal Changes in Blood Biomarkers of Dementia With the Proportion of Genetically Inferred African Ancestry.Neurology · 2025Article
- Late-life emergence of neuropsychiatric symptoms and risk of cognitive impairment in cognitively unimpaired individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Total and Structural Carotid Artery Stiffness Are Associated With Cognitive Decline and Structural Brain Abnormalities Related to Alzheimer Disease and Alzheimer Disease-Related Dementias Pathology: The Multi-Ethnic Study of Atherosclerosis.Journal of the American Heart Association · 2025Article
- Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries.JAMA network open · 2025Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAfrican Americans have been reported to have a higher prevalence of Alzheimer's disease (AD) than Caucasians, but etiology-specific AD biomarkers have not been systematically analyzed in older African Americans. Coexisting cerebrovascular disease may also contribute to this increased prevalence. We hypothesized that cerebrospinal fluid (CSF) biomarkers of amyloid, neurodegeneration, and endothelial dysfunction would differ between older African Americans and Caucasians with normal cognition and cognitive impairment associated with AD.
methodsWe prospectively recruited 135 older Americans to undergo detailed clinical, neuropsychological, genetic, magnetic resonance imaging (MRI), and CSF analysis from 2013 to 2015 at Emory University (Atlanta, GA, USA). We compared levels of CSF markers for β-amyloid (Aβ42, Aβ40), total and phosphorylated tau (t-tau and p-tau
resultsSixty-five older African Americans (average age, 69.1 years) and 70 older Caucasians (average age, 70.8 years) were included. After adjusting for demographic variables, AD risk alleles, and cognitive function, older African Americans had lower CSF levels of p-tau
conclusionsDespite comparable levels of CSF Aβ42 and Aβ42/Aβ40, cognitive impairment in African Americans is associated with smaller changes in CSF tau markers but greater impact from similar WMH burden than Caucasians. Race-associated differences in CSF tau markers and ratios may lead to underdiagnosis of AD in African Americans.
trial registrationClinicalTrials.gov, NCT02089555 . Retrospectively registered on 14 March 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.